NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions: Cognitive Change
Interventions: EMRESERVA
Countries: Spain
Multiple Sclerosis(MS) is an immunological degenerative disease that affects central nervous system causing cognitive impairment, which is one of the most disabling symptoms in MS. Cognitive reserve may influence manifestations of symptoms of cognitive impairment in MS patients and could justify interindividual differences. Cognitive reserve hypothesis raises that enriching life experiences creates a higher capacity and efficiency of neural networks and protects against cognitive decline in neurological diseases. Scientific evidence demonstrates that older adults with a higher educational,occupational attainment or engagement in cognitively stimulating leisure activities have a reduced risk of dementia.Systematic reviews report little efficacy of pharmacological and behavioral treatments impairment in cognitive functions in MS patients . As such, best treatment of cognitive impairment in MS may be a proactive prevention of cognitive decline in first place Through the application of the EM-Reserva program our goal is to evaluate if it is possible to improve cognitive skills of patients with MS without cognitive impairment versus those who undergo non-specific cognitive exercises. In the short and medium term, EM-Reserva program could improve cognitive performance and delay the appearance or modulate the severity of cognitive impairment in the course of the disease
Sex: ALL
Age: 18 Years to 55 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Aged 18-55 years (both inclusive). * Relapsing-remitting Multiple Sclerosis (RRMS) according to the 2017 McDonald Revised Criteria with less than 15 years of evolution. * Patients with EDSS \<3 * No cognitive impairment on the Brief Neuropsychological Battery of Rao (BRB-N) (Form A) corrected for age and education performed on the last three months in the MS Unit of Hospital Virgen Macarena (UEMAC) according to Amato´s criteria * Able to attend group sessions. * Patients able to give written Informed Consent. Exclusion Criteria: * Diagnosis of Secondary Progressive or Primary Progressive MS according to McDonald revised criteria (2017) * No evidence of relapse or corticosteroid treatment in the 3 months prior to study inclusion. * Had vision or hearing problems, such that they were unable to complete the cognitive assessments. * Had concurrent severe medical or psychiatric conditions, which prevented them from engaging in treatment and/or Beck Depression Inventory \> 20. * Involved in other psychological intervention trials.
- Seville, Andalusia, Spain